Welcome to our dedicated page for Ibex SEC filings (Ticker: IBEX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The IBEX Limited (IBEX) SEC filings page on Stock Titan provides direct access to the company’s regulatory disclosures, along with AI-powered tools to help interpret them. As a Nasdaq-listed Bermuda company and emerging growth issuer, IBEX files a range of documents with the U.S. Securities and Exchange Commission that detail its operations, governance, and financial performance.
Key filings include Form 10-K and related annual reports, which present audited financial statements, risk factors, and management’s discussion of results for the fiscal year. Quarterly results and updates are frequently communicated through Form 8-K, where ibex furnishes press releases covering revenue, net income, adjusted net income, adjusted EBITDA, and earnings per share, as well as guidance ranges for future periods.
Investors can also review proxy materials such as the DEF 14A, which describe the board structure, director independence, committee composition, executive compensation programs, long-term incentive plans, and changes in status such as the transition away from controlled company exemptions. Other 8-K filings address governance developments, including the formation of a formal Nominating Committee and related board decisions.
Stock Titan enhances these filings with AI-powered summaries and explanations that highlight important sections, clarify technical language, and surface items that may matter to shareholders, such as governance changes, compensation plans, or capital allocation decisions. Real-time updates from EDGAR ensure that new IBEX filings, including Forms 3, 4, and 5 for insider transactions when available, appear promptly.
Use this page to explore IBEX’s historical and current SEC record, understand how management presents its strategy and performance, and quickly grasp the implications of lengthy documents through AI-generated insights.
IBEX Ltd (IBEX) reporting person Taylor C. Greenwald, Chief Financial Officer, sold 2,295 common shares on 09/19/2025 at $40.7302 per share. The Form 4 shows the sale was required to cover tax withholding for restricted stock units that vested and is not described as a discretionary trade. After the transaction the reporting person beneficially owned 33,561 shares, held directly. The filing was signed by an attorney-in-fact on 09/23/2025. No options, derivative transactions, or other compensatory arrangements are disclosed on this Form 4.
Julie K. Casteel, Chief Sales/Marketing Officer of IBEX Ltd (IBEX), reported a sale of common shares. On 09/16/2025 she disposed of 5,000 common shares at a price of $39.0002 per share, leaving her with 25,895 shares beneficially owned. The Form 4 was signed by an attorney-in-fact on 09/17/2025.
IBEX Ltd filed a Form 144 notice disclosing a proposed sale of 5,000 shares of its common stock by an insider. The filing names Charles Schwab as the broker and lists an approximate sale date of 09/16/2025 on Nasdaq. The shares were acquired as stock grants on 12/31/2018 and paid via equity compensation. The filing also reports a recent sale of 295 shares on 07/01/2025 for $8,592. The filer affirms no undisclosed material adverse information.
IBEX Ltd Form 4 summary: The filing by Bruce Neil Dawson reports transactions in IBEX Ltd (IBEX) on 09/16/2025. The reporting person executed an acquisition of 8,114 common shares (code M) at a reported price of $19.00, and two sales of common shares the same date: 8,114 shares sold at a weighted average price of $38.14 and 765 shares sold at a reported price of $38.2903. Following the reported transactions, the filing shows beneficial ownership levels of 13,371, 5,257, and 4,492 shares on the respective lines. The seller notes the sales were executed in multiple trades at prices ranging from $38.2901 to $38.35 and offers to provide further breakdowns on request. The form is signed by an attorney-in-fact, Lisa Lenstrohm, dated 09/17/2025.
IBEX Ltd insider Robert Thomas Dechant reported same-day non-derivative transactions on 09/16/2025. He acquired 45,027 common shares at $19.00, bringing his beneficial ownership to 237,026 shares (direct), and sold 45,027 common shares at $38.89, leaving 191,999 shares (direct) after the transactions. The Form 4 was signed by an attorney-in-fact on 09/17/2025.
Form 4 shows that Christina Trofimuk-O'Connor, Chief Legal Officer of IBEX Ltd (IBEX), reported a sale of 844 common shares on 09/16/2025 at a price of $38.50 per share. After the reported transaction she beneficially owns 11,727 shares, held directly. The filing was made as a single reporting person and signed by an attorney-in-fact on 09/17/2025.
IBEX Ltd (Form 144): A proposed sale of 8,114 common shares is notified for sale on 09/16/2025 through Global Shares Financial Services Inc. The filing reports an aggregate market value of $309,467.96 and lists 13,315,077 shares outstanding for the issuer. The shares were originally acquired on 08/07/2020 as a grant from the issuer. The filer also reported a recent sale of 350 shares on 08/26/2025 generating $10,194.36 in gross proceeds. The notice includes the required representation that the seller is not aware of any undisclosed material adverse information about the issuer.
Form 144 notice for IBEX Ltd shows a proposed sale of 45,027 common shares by the person named, with an aggregate market value of $1,751,100.03 and an approximate sale date of 09/16/2025 on NASDAQ. The shares were acquired as a grant on 08/07/2020. The filing also discloses a prior sale by the same person of 1,634 shares on 08/26/2025 for gross proceeds of $47,593.10. The filer certifies they have no undisclosed material adverse information about the issuer and includes the standard Rule 144 attestation language.
Form 144 filed for IBEX Ltd (IBEX) reports a proposed sale of 844 shares of common stock valued at $32,494 with an approximate sale date of 09/16/2025 on NASDAQ. The shares were acquired by the seller as a stock grant from the issuer on 07/01/2025 (1,210 shares acquired in that grant). The filing also discloses a prior disposal by the same person of 366 shares on 08/26/2025 for gross proceeds of $10,660.39. The filer certifies they have no material nonpublic information about the issuer.
Insider sale by IBEX Ltd CFO to satisfy tax withholding from RSU vesting. Taylor C. Greenwald, listed as Chief Financial Officer, reported a sale of 438 common shares on 08/26/2025 at a price of $29.13 per share. The filing states the shares were sold to cover tax withholding obligations related to the vesting of restricted stock units and were not discretionary trades. After the transaction, the reporting person beneficially owned 35,856 shares, held directly. The Form 4 was signed by an attorney-in-fact, Lisa Lenstrohm, on 09/15/2025.
FAQ
What is the current stock price of Ibex (IBEX)?
What is the market cap of Ibex (IBEX)?
